Bill Alpert
Senior Writer at Barron's
Bill Alpert is a Senior Writer at Barron’s, where since 1984 he has published nerdy feature stories, columns and investigative projects of use to investors.
Articles
-
1 week ago |
barrons.com | Bill Alpert
After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly , another class of weight-loss drugs called amylins is drawing the drug industry’s attention and dollars.
-
2 weeks ago |
barrons.com | Bill Alpert
Forty years after the first statin drug started lowering levels of artery-choking cholesterol, heart attacks and strokes remain the world’s biggest killers. This year, we’ll see test results on some drugs that cut cholesterol even more.
-
2 weeks ago |
flipboard.com | Bill Alpert
11 hours agoAI Shows Higher Emotional IQ than HumansA new study tested whether artificial intelligence can demonstrate emotional intelligence by evaluating six generative AIs, including ChatGPT, on …19 hours agoThis Skill Can Help You Unlock an Altered State of Consciousness—And Mimic the Way Marijuana FeelsIt may be one of evolution’s greatest tricks yet. Euphoria. Mental clarity. Heightened awareness. Reduced pain. Zen.
-
2 weeks ago |
barrons.com | Bill Alpert
Soon after taking charge of the Securities and Exchange Commission this year, Republican administrators acted to partly blind a market surveillance system the agency had taken 15 years to build. Now, the Consolidated Audit Trail no longer collects identifying information on American traders.
-
3 weeks ago |
barrons.com | Bill Alpert
California regulators granted an emergency rate hike Tuesday to State Farm, the biggest home insurer in that state and the nation.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 941
- DMs Open
- Yes
Less Loose Lending at the #SBA The Small Business Administration Reinstates Sober Lending Standards https://t.co/gIGt0cHhNF via @BarronsOnline
#MRUS is a rare biotech favorite Merus Will Have a Best-in-Class Treatment for Head and Neck Cancer, Analysts Say https://t.co/JQ75cMv7CV via @BarronsOnline
After #ILMN debacle, this analyst thinks #GRAL deserves a look This Cancer Test Could Become Routine—and a Big Seller, Says Analyst https://t.co/XsZHtoz7kG via @BarronsOnline